DOMH vs. XOMA, VNDA, VSTM, CDXS, SGMO, AGEN, IRWD, ACHV, FBIO, and CRIS
Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Sangamo Therapeutics (SGMO), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.
Dominari vs. Its Competitors
XOMA Royalty (NASDAQ:XOMA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.
XOMA Royalty has a net margin of -13.04% compared to Dominari's net margin of -167.73%. XOMA Royalty's return on equity of -12.43% beat Dominari's return on equity.
In the previous week, XOMA Royalty had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for XOMA Royalty and 0 mentions for Dominari. XOMA Royalty's average media sentiment score of 0.74 beat Dominari's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.
XOMA Royalty presently has a consensus target price of $69.50, suggesting a potential upside of 145.00%. Given XOMA Royalty's stronger consensus rating and higher possible upside, equities research analysts clearly believe XOMA Royalty is more favorable than Dominari.
XOMA Royalty has higher revenue and earnings than Dominari. XOMA Royalty is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
XOMA Royalty has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Comparatively, 33.0% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
XOMA Royalty beats Dominari on 14 of the 16 factors compared between the two stocks.
Get Dominari News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Dominari Competitors List
Related Companies and Tools
This page (NASDAQ:DOMH) was last updated on 7/10/2025 by MarketBeat.com Staff